Mirikizumab API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Mirikizumab API 1884201-71-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Mirikizumab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Mirikizumab
- Synonyms:
- Cas Number:
- 1884201-71-1
- DrugBank number:
- DB14910
- Unique Ingredient Identifier:
- Z7HVY03PHP
General Description:
Mirikizumab, identified by CAS number 1884201-71-1, is a notable compound with significant therapeutic applications. Mirikizumab is under investigation in clinical trial NCT03053622 (A Study of Mirikizumab (LY3074828) Injection in Healthy Participants).
Categories:
Mirikizumab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Analgesics, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Blood Proteins, Gastrointestinal Agents, Globulins, Immunoglobulins, Immunoproteins, Peripheral Nervous System Agents, Proteins, Sensory System Agents, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Mirikizumab is a type of Anti-inflammatory Agents
Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.
Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.
Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.
In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.
